Shopping Cart
- Remove All
Your shopping cart is currently empty
SGR-1505, an orally active MALT1 allosteric inhibitor, reduces MALT1 enzymatic activity and demonstrates anti-proliferative effects in both BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 is applicable for B-cell lymphoma research [1].

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks |
| Description | SGR-1505, an orally active MALT1 allosteric inhibitor, reduces MALT1 enzymatic activity and demonstrates anti-proliferative effects in both BTK inhibitor (BTKi)-sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 is applicable for B-cell lymphoma research [1]. |
| Molecular Weight | 481.79 |
| Formula | C18H12ClF4N9O |
| Cas No. | 2661481-41-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.